Understanding Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus⁢ (RSV) is a highly‍ contagious virus⁤ that infects the lungs and respiratory tract. While often ⁢causing ⁢mild, cold-like symptoms, RSV⁢ can be severe – even life-threatening – for ⁢vulnerable populations, including infants, young children, and older adults. Until recently, treatment options were ⁢limited to supportive care.

Prior to the 2023 approvals, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000⁢ deaths annually among adults 65 years⁤ and ⁣older in the United States. The virus causes inflammation and fluid in the lungs, leading to ‍breathing difficulties and possibly pneumonia.

The Landmark Approval of Arexvy and⁢ Abrysvo

On May 3, 2023, the Food⁣ and ‍Drug ⁤Management (FDA) approved Arexvy, a subunit vaccine developed by GSK, for the prevention ‍of RSV-associated lower respiratory tract disease (LRTD) in adults ⁢aged 60 years and older. This marked ⁤a significant milestone ⁣in public health, representing ⁤the first FDA-approved RSV vaccine for this age group. Shortly after,on August⁤ 21,2023,Pfizer’s Abrysvo also received FDA approval.

The approval ⁢was based on data from the RSVAPEX trial, a large, ⁢randomized,‍ placebo-controlled study involving‍ nearly 25,000 adults. Results published in the New England Journal of Medicine on October 9, 2025, demonstrated that Arexvy was 82.6% effective in⁣ preventing RSV-associated LRTD with a symptom ‍burden score of 3 or‍ higher. ‍ The vaccine also showed ‍a 94.1% efficacy against severe RSV-associated LRTD.

Abrysvo demonstrated similar efficacy in ⁤clinical trials,with approximately 82.6% efficacy against RSV-associated LRTD ⁣in⁤ adults ‍60 ‍years and older. Notably, Abrysvo also⁣ showed maternal transfer of antibodies, offering potential protection to infants.

Clinical Trial Details and Efficacy Data

The RSVAPEX trial, crucial to Arexvy’s⁢ approval, enrolled participants aged 60 years and older across multiple countries. participants were randomly assigned to ⁤receive either the Arexvy vaccine or a placebo.The primary⁤ endpoint was RSV-associated LRTD with a symptom burden score of 3 or higher, assessed using a ⁤validated scale.